Results 71 to 80 of about 157,757 (356)

Chemiluminescent Biosensors for Detection of Second Messenger Cyclic di-GMP

open access: yes, 2018
Bacteria colonize highly diverse and complex environments, from gastrointestinal tracts to soil and plant surfaces. This colonization process is controlled in part by the intracellular signal cyclic di-GMP, which regulates bacterial motility and biofilm ...
Dippel, Andrew B   +14 more
core   +1 more source

A Cyclic Di-GMP Network Is Present in Gram-Positive Streptococcus and Gram-Negative Proteus Species [PDF]

open access: yes, 2020
Cyclic di-GMP is a ubiquitous second messenger in bacteria. This work describes the occurrence of a cyclic di-GMP signaling network in Gram-positive Streptococcus species and Gram-negative Proteus.
Rey-Ting, Guo   +9 more
core   +1 more source

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

open access: yesAdvanced Healthcare Materials, EarlyView.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj   +23 more
wiley   +1 more source

The ins and outs of cyclic di-GMP signaling in Vibrio cholerae

open access: yesCurrent Opinion in Microbiology, 2017
The second messenger nucleotide cyclic dimeric guanosine monophosphate (c-di-GMP) governs many cellular processes in the facultative human pathogen Vibrio cholerae.
Jenna G Conner   +4 more
semanticscholar   +1 more source

Differential expression between GMP and GMP like.

open access: yes, 2023
Related to Fig 3. (A) The heatmap showing the expression levels of normal HSC progenitor, GMP, myeloid and AML HSC-like, progenitor-like, GMP-like makers in the Galen and colleagues, Cell 2019 (rows) in tipping point HSPC, GMP, and GMP-like cells ...
Chong Chen (360710)   +17 more
core   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

open access: yesAdvanced Healthcare Materials, EarlyView.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave   +8 more
wiley   +1 more source

Pelatihan Good Manufacturing Practice (GMP) pada Usaha Pangan Binaan Universitas Andalas

open access: yesWarta Pengabdian Andalas, 2020
Food business is a very promising, but the products must be safe and worth buying. Good manufacturing practices (GMP) are production practices which considering various aspects, such as preventing food contamination during the production process, and ...
Tivany Edwin   +4 more
doaj   +1 more source

The regulation of alginate biosynthesis via cyclic di-GMP signaling

open access: yes, 2020
Bacterial alginates are anionic exopolysaccharides, which are produced by Pseudomonas and Azotobacter species. Bacterial cells embedded in extracellular polymeric substances such as alginates have a survival advantage as they are protected against ...
Rehm, BHA, Moradali, MF
core   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

open access: yesAdvanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans   +7 more
wiley   +1 more source

Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU

open access: yesPharmaceutics, 2020
The latest advances in pharmaceutical technology are leading to the development of cutting edged approaches to produce what is now known as the “Holy Grail” of medicine—nanopharmaceutics.
Eliana B. Souto   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy